These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. Mekkaoui C; Jadbabaie F; Dione DP; Meoli DF; Purushothaman K; Belardinelli L; Sinusas AJ JACC Cardiovasc Imaging; 2009 Oct; 2(10):1198-208. PubMed ID: 19833310 [TBL] [Abstract][Full Text] [Related]
3. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications. Palani G; Ananthasubramaniam K Cardiol Rev; 2013; 21(1):42-8. PubMed ID: 22643345 [TBL] [Abstract][Full Text] [Related]
4. An example of the clinical selectivity of regadenoson for the A2a adenosine receptor. Miyamoto MI; Clarke KA; Thomas GS; Belardinelli L Am Heart Hosp J; 2009; 7(2):E118-21. PubMed ID: 20354957 [No Abstract] [Full Text] [Related]
5. Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. Johnson NP; Gould KL JACC Cardiovasc Imaging; 2015 Apr; 8(4):438-447. PubMed ID: 25797122 [TBL] [Abstract][Full Text] [Related]
7. Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole. Friedman M; Spalding J; Kothari S; Wu Y; Gatt E; Boulanger L J Med Econ; 2013; 16(4):449-60. PubMed ID: 23363331 [TBL] [Abstract][Full Text] [Related]
8. Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity. Kitkungvan D; Bui L; Johnson NP; Patel MB; Roby AE; Vejpongsa P; Babar AK; Madjid M; Nacimbene A; Kumar S; DeGolovine A; Gould KL Eur Heart J Cardiovasc Imaging; 2019 Jul; 20(7):751-762. PubMed ID: 31056681 [TBL] [Abstract][Full Text] [Related]
9. Regadenoson myocardial perfusion imaging predicts prognosis in patients with either left bundle branch block or a ventricular paced rhythm. Thomas GS; Taghavi A J Nucl Cardiol; 2021 Jun; 28(3):978-980. PubMed ID: 31385224 [No Abstract] [Full Text] [Related]
10. Does a shortened hyperemia with regadenoson stress pose a concern for quantitative Rb-82 PET imaging? Optimization of regadenoson PET imaging. Sinusas AJ JACC Cardiovasc Imaging; 2015 Apr; 8(4):448-450. PubMed ID: 25882574 [No Abstract] [Full Text] [Related]
12. Advances in pharmacologic stress agents: focus on regadenoson. Johnson SG; Peters S J Nucl Med Technol; 2010 Sep; 38(3):163-71. PubMed ID: 20724531 [TBL] [Abstract][Full Text] [Related]
13. ST segment elevation during adenosine pharmacological stress testing in a patient with coronary artery disease. Raza JA; Khan NU; Mustafa JS; Movahed A Am Heart Hosp J; 2009; 7(2):E122-4. PubMed ID: 20354958 [No Abstract] [Full Text] [Related]
14. Patient- and clinician-reported satisfaction with pharmacological stress agents for single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). Hudgens S; Breeze J; Spalding J J Med Econ; 2013; 16(6):828-34. PubMed ID: 23614479 [TBL] [Abstract][Full Text] [Related]
15. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands]. Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658 [TBL] [Abstract][Full Text] [Related]
16. Connectivity of radiotracers to vasodilators is thallium the missing link? Dilsizian V JACC Cardiovasc Imaging; 2009 Oct; 2(10):1209-12. PubMed ID: 19833311 [No Abstract] [Full Text] [Related]
17. Comparing prognostic value of imaging agents and imaging techniques. Udelson JE JACC Cardiovasc Imaging; 2012 Oct; 5(10):1022-4. PubMed ID: 23058069 [No Abstract] [Full Text] [Related]
18. Magnetic resonance stress imaging of myocardial perfusion and wall motion. Kawel-Boehm N; Bremerich J J Thorac Imaging; 2014 Jan; 29(1):30-7. PubMed ID: 24157620 [TBL] [Abstract][Full Text] [Related]